Trial reportNature communications2022
Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma.
Trial report in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03282344 (A Pilot Study of NKTR-214 and Nivolumab in Selected Patients With Locally Advanced/Metastatic Sarcoma), which is not on this map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study of NKTR-214 and Nivolumab in Selected Patients With Locally Advanced/Metastatic Sarcoma (CA209-9EM)
Who cites it
45 citing papers in PubMed, 54 citations in OpenAlex.
- Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial.Cancer · 2025Trial
- A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses.Journal for immunotherapy of cancer · 2024Trial
- The promise of immunotherapy in the treatment of sarcoma: A state-of-the-art review of practice changing research and future directions.Human vaccines & immunotherapeutics · 2026Review
- Immunotherapy combined with anti-angiogenic therapy, radiotherapy and chemotherapy for the treatment of giant pelvic osteosarcoma: A case report and literature review.Oncology letters · 2026Article
- The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.Current treatment options in oncology · 2026Review
- Concomitant Medication Effects on Immunotherapy Outcomes in Sarcoma: A Pooled Post Hoc Analysis of Seven Phase II Trials.Cancer medicine · 2026Article
- Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Advances in IL-2 Family Cytokine-Based Cancer Therapies: Overcoming Challenges Through Molecular Engineering and Delivery Strategies.Immune network · 2026Review
- Immunotherapy for Leiomyosarcoma: Current Status and Perspectives.Journal of immunology research · 2026Review
- Immunotherapy and postoperative bone defect repair strategies based on osteosarcoma tumor microenvironment characteristics: balancing antitumor effects and promotion of bone regeneration.Regenerative biomaterials · 2026Review
- Osteosarcoma as a communication-driven disease: redefining tumor-bone signaling networks as therapeutic targets.Frontiers in oncology · 2026Review
- Overcoming barriers in primary bone cancer: Nanomaterial-enabled immunotherapy.Materials today. Bio · 2025Review
- Genetic Heterogeneity of Undifferentiated Pleomorphic Sarcoma: Is There Potential for Targeted Therapy?Cancers · 2025Review
- Immunotherapy in the Treatment of Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma.Current treatment options in oncology · 2025Review
- Blood-based biomarkers in soft tissue sarcoma: Implications for immune checkpoint inhibitor therapy.International journal of cancer · 2025Review
- High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapy.Journal for immunotherapy of cancer · 2025Article
- Adjusting the scope of natural killer cells in cancer therapy.Cellular & molecular immunology · 2025Review
- Angiosarcoma: Role of Immunotherapy.Current treatment options in oncology · 2025Review
- Immunologic correlates in a CIC::DUX4 fusion-positive sarcoma responsive to dual immune checkpoint blockade.NPJ precision oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 2 institutions in 1 country.
Funding
Abstract
PD-1 blockade (nivolumab) efficacy remains modest for metastatic sarcoma. In this paper, we present an open-label, non-randomized, non-comparative pilot study of bempegaldesleukin, a CD122-preferential interleukin-2 pathway agonist, with nivolumab in refractory sarcoma at Memorial Sloan Kettering/MD Anderson Cancer Centers (NCT03282344). We report on the primary outcome of objective response rate (ORR) and secondary endpoints of toxicity, clinical benefit, progression-free survival, overall survival, and durations of response/treatment. In 84 patients in 9 histotype cohorts, all patients experienced ≥1 adverse event and treatment-related adverse event; 1 death was possibly treatment-related. ORR was highest in angiosarcoma (3/8) and undifferentiated pleomorphic sarcoma (2/10), meeting predefined endpoints. Results of our exploratory investigation of predictive biomarkers show: CD8 + T cell infiltrates and PD-1 expression correlate with improved ORR; upregulation of immune-related pathways correlate with improved efficacy; Hedgehog pathway expression correlate with resistance. Exploration of this combination in selected sarcomas, and of Hedgehog signaling as a predictive biomarker, warrants further study in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.